Abstract: Fibrogenesis is the active production of extracellular matrix in response to tissue injury.I nm any chronic diseases persistent fibrogenesis results in the accumulation of scar tissue,which can lead to organ failure and death. However,no non-invasive techniquee xists to assess this key biological process.A ll tissue fibrogenesis results in the formation of allysine,w hich enables collagen cross-linking and leads to tissue stiffening and scar formation. We report herein an ovel allysine-binding gadolinium chelate (GdOA), that can noninvasively detect and quantify the extent of fibrogenesis using magnetic resonance imaging (MRI). We demonstrate that GdOAs ignal enhancement correlates with the extent of the disease and is sensitive to atherapeutic response.
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Almost half of the deaths in the industrialized world can be attributed to diseases with af ibroproliferative component. [1] In the lung,p ulmonary fibrosis constitutes am ajor cause of morbidity and mortality.Idiopathic pulmonary fibrosis (IPF), the most common and most lethal diffuse fibrosing lung disease,isresponsible for an estimated 40 000 deaths per year in the US. [2] Pulmonary fibrosis is characterized by the accumulation of myofibroblasts and their production of an excess of extracellular matrix (ECM) proteins.T hough this ECM accumulation and remodeling,t ermed fibrogenesis,i s an innate part of the natural wound healing process,u nder persistent injury excess ECM results in ab uild up of scar tissue causing the loss of tissue function and potential organ failure and mortality. [3] High-resolution computed tomography is invaluable for the diagnosis of IPF [4] but cannot distinguish regions of active fibrogenesis from stable scar tissue.M olecular MRI, to quantify the extent of increased ECM components,b y direct targeting of the collagen deposition that occurs during scar tissue formation, has previously been used to image fibrosis. [5] While this provides am eans to quantify the changes in total fibrotic burden of apatient, collagen imaging does not provide ameasure of the dynamic changes occurring at the molecular level during fibrogenesis.I maging fibrogenesis would identify patients whose disease is progressing and would also enable the monitoring of treatment with drugs that could stop or slow fibrotic progression.
Au niversal feature of fibrogenesis is the oxidation of ECM lysine residues,c hiefly in collagen, to the aldehyde allysine by the lysyl-oxidase (LOX) family of enzymes. Allysine [6] undergoes as eries of condensation reactions with other amino acids on neighboring collagen molecules (Supporting Information, Figure S1 ) to form irreversible crosslinks that stabilize the ECM, and is af undamental feature across all fibrotic diseases. [7] While lysine oxidation is catalyzed by LOX, the subsequent condensation reactions of allysine are slower.W er easoned that allysine could be at arget for imaging fibrogenesis.I na ctive fibrogenesis,a n increased pool of allysine would be generated, but in astable disease state or with therapeutic intervention these allysine moieties would be converted to crosslinks.
To determine if allysine was sufficiently abundant for detection with MRI, we quantified allysine in mouse lung tissue using HPLC.N ormal and fibrotic lung tissue was digested at 110 8 8Ci n6 m HCl for 24 h, and the allysine derivatized with 2-naphthol-7-sulfonate to yield afluorescent molecule that could be detected and quantified by HPLC. [8] In normal mouse lung,t here was 80 AE 6nmol allysine per gram of lung tissue,a pproximately 80 mm.I nm ice injured with bleomycin, the allysine content was increased to 150 AE 16 nmol allysine per gram of lung tissue.S uch high micromolar concentrations are readily detectable by Gd-enhanced MRI.
In the design of ap robe for MR imaging of fibrogenesis, certain criteria are essential, including:1 )high thermodynamic and kinetic chelate stability,2 )high water solubility, 3) rapid renal excretion, 4) low non-target background uptake,5 )rapid penetration into the tissue interstitial space and 6) target selectivity.T os atisfy these criteria, we developed GdOA, an oxyamine-functionalized derivative of GdDOTA for targeting allysine.The GdDOTAcore provides ahighly stable and inert Gd-chelate (Supporting Information, Figure S2 ). Thea nionic and hydrophilic nature of GdOA results in high solubility,reduces nonspecific protein binding, and promotes rapid renal elimination. Fort arget selectivity, an oxyamine was selected, as the oxime formed from the reaction of an aldehyde with an oxyamine is known to be more stable to hydrolysis than the analogous hydrazone or imine [9] and is therefore expected to result in as trong MR signal enhancement on binding to allysine.
GdOA( Figure 1a and the Supporting Information, Scheme 1) was prepared by coupling the NHS active-ester of N-Boc-aminooxyacetic acid [10] with an amine-functionalized derivative of DOTA( DOTA-NH 2 ), followed by Bocdeprotection in 1m HCl, with subsequent Gd chelation at pH 6.8. GdOAp urity was assessed by HPLC-ICP-MS analysis,w ith as ingle Gd species identified and confirmed as GdOAbyHPLC-MS analysis.Asix-carbon chain was used as alinker to minimize interaction between the GdDOTAc ore and oxyamine.Asanegative control, GdOX was synthesized, which has the same pharmacokinetic properties of GdOAbut is incapable of undergoing ac ondensation reaction with allysine ( Figure 1a and the Supporting Information, Scheme 2).
Ther elaxivity (1.4 T, 37 8 8C) of GdOAw as similar when measured in PBS solution (4.25 mm À1 s À1 )orinPBS with 3mg of bovine serum albumin (BSA, 150 mm)i ndicating very low nonspecific protein binding. However,inthe presence of 3mg of BSA-Ald:B SA that had been oxidized with FeCl 3 / aspartate to generate 16 nmol of aldehydes per milligram of protein, [11] relaxivity increased by 90 %t o8 .10 mm À1 s
À1
( Figure 1b) ; the protein-bound fraction of GdOAh ad ar elaxivity of 16.87 mm À1 s À1 .G dOX showed an egligible increase in relaxivity in the presence of BSA or oxidized BSA-Ald. Quantification of the GdOAprobe bound to BSAAld, following ultrafiltration and ICP-MS analysis,g ave abinding constant of 164 mm (Figure 1c) . To assess inertness, GdOAwas challenged with zinc and phosphate and showed no Gd release (Supporting Information, Figure S2) .
Next, the binding of GdOAt ot issue was assessed. The aorta is rich in allysine as aresult of high lysyl-oxidase activity and turnover of elastin and collagen. We measured 7.50 mmol of allysine per gram of porcine aorta using the HPLC assay. We then incubated GdOAo rG dOXw ith segments of aorta (25 mg of aorta tissue,3 7 8 8C, 24 h, pH 7). After repeated washing to remove non-specifically bound probe,t he aortaassociated Gd was quantified by ICP-MS.GdOAgave a K d of 360 mm,while GdOXshowed no affinity (Figure 1d ).
Thep harmacokinetics of GdOAa nd GdOX were assessed in naive mice using MR imaging to measure the blood MR signal wash-out from the left ventricle of the heart. Both probes displayed rapid and almost identical blood clearances with blood half-lives of 5.5 and 6.1 min for GdOA and GdOXr espectively,i ndicating comparable probe pharmacokinetics (Supporting Information, Figure S3 ). Elimination was exclusively through the kidneys with minimal, transient liver enhancement observed. Biodistribution of GdOAa t1 ha fter bolus intravenous injection in naive C57Bl/6 mice showed that 95 %o ft he injected dose had already been eliminated from the body (Supporting Information, Table S1 ).
Thea bility of GdOAt od etect and stage pulmonary fibrogenesis was then evaluated using ableomycin lung-injury mouse model. Bleomycin is achemotherapeutic antibiotic, [12] but amajor adverse effect of bleomycin is the overproduction of reactive oxygen species in the lung, [13] which can lead to fibrosis. [14] Mice injured with bleomycin rapidly and reliably develop pulmonary fibrosis. [15] We studied four groups of C57Bl/6 mice:1 )mice injured with as ingle intratracheal administration of bleomycin (Bleo), 2) age-matched healthy mice (Naive), 3) mice injured with bleomycin and then dosed daily with the pan-LOXi nhibitor b-aminopropionitrile (BAPN,1 00 mg kg À1 )( Bleo + BAPN), [16] and 4) mice injured with bleomycin and then dosed daily with PBS as av ehicle control (Bleo + PBS). After 14 days,m ice were imaged before and after intravenous injection of 100 mmol kg
GdOA( all four cohorts) or GdOX( first two cohorts), the same dose as used for most clinical GdDOTA-enhanced MRI exams. [17] Bleomycin-injured mice demonstrated increased pulmonary fibrosis as measured by the Ashcroft system of histology scoring (Supporting Information, Figure S4 ). Bleomycininjured mice had 3.4-fold higher lung LOXactivity (Figure 2a and the Supporting Information, Figure S5 ), 1.75-fold higher collagen content (Supporting Information, Figure S6 ), and 2.1-fold higher allysine content (Figure 2band the Supporting Information, Figure S7 ) than in naive animals.T reatment with the LOXinhibitor BAPN reduced the lung LOXactivity and allysine content to levels observed in naive mice,a lthough BAPN had no effect on total lung collagen levels (Figure 2a ,b and the Supporting Information, Figure S6) .
It is well known that T2* in the lung is very short (ca. 1ms) because of the magnetic susceptibility gradients caused by the air-tissue interface.T oo vercome this signal loss we used an ultrashort echo time (UTE) sequence.T1-weighted UTE MR images were taken before and after injection of GdOAo r GdOX ( Figure 2c ,d,g and the Supporting Information, Figure S8 ), starting at 12 min when the background blood signal was minimal and lung signal intensity was highest. Thel ung signal and adjacent skeletal muscle signal were measured before and after probe injection, and the change in lung-tomuscle signal ratio (DLMR) (Figure 2e and the Supporting Information, Figure S9 ) was calculated, where LMR = SI lung / SI muscle (SI = signal intensity) and DLMR = LMR post ÀLMR pre . GdOAinjection resulted in astrong lung signal enhancement in bleomycin-injured lungs compared to naive mice.T he signal enhancement correlated strongly with the extent of disease (Supporting Information, Figure S10 ). GdOXi njection resulted in as imilar, weak lung enhancement in both bleomycin and naive mice,i ndicating that the oxyamine function was required for the higher signal observed in the bleomycin-injured mice.B APN treatment did not inhibit collagen production (Supporting Information, Figure S6 ) but did prevent allysine production and crosslinking (Figure 2b ). MRI indicated that GdOAi ss ensitive to the allysine reduction caused by BAPN,f urther demonstrating the specificity of GdOA ( Figure 2h ). We also compared the change in liver-to-muscle ratio between naive and bleomycingroups after GdOAa nd saw no significant difference in signal, suggesting that the increased GdOAl ung enhancement observed in bleomycin-mice is disease-dependent (Supporting Information, Figure S11 ). Ex vivo analysis of lung Gd confirmed the imaging results,w ith the micromolar Gd lung concentrations measured consistent with the image enhancement observed (Figure 2f and the Supporting Information, Figure S12 ).
In summary,w es howed that allysine is as uitable target for molecular MR detection of fibrogenesis.T he novel probe GdOAisstable with respect to Gd release and is able to bind to oxidized collagen present during fibrogenesis.G dOA shows rapid uptake in adisease model of pulmonary fibrosis and demonstrates specific allysine targeting resulting in an enhanced MRI signal in fibrotic tissue.G dOAs hows low nonspecific binding and rapid background clearance.G dOA imaging provides aq uantitative non-invasive measure of the extent of active fibrogenesis in fibrotic diseases.T argeting allysine as areadout of the rate of fibrogenesis may allow for the determination of fibrotic disease activity across all tissue types. Figure 2 . Post imaging ex vivo tissue analyses for GdOA and GdOX in naive mice, 14 day bleomycin (Bleo) mice and 14 day bleomycin + daily BAPN (Bleo + BAPN) treated mice, and representative coronal MR images with overlaid lung enhancement (shown in false color). a) Total LOX activity levels increasedi nBleo-treated mice compared to naive animals. Daily BAPN dosing reduces LOX activity levels in Bleo + BAPN animals down to similar levels seen in naive mice;b)allysine lung-concentration levels track with LOX activity,w ith asignificant increase in Bleo mice compared to naive animals and asignificant decrease in Bleo + BAPN animals;c )GdOA uptake in naive mouse, showing low MR signal enhancement in healthy lungs;d)GdOA uptake in bleomycin-treated mouse, showing strong lung enhancement in 14 day bleomycin-injured mice;e)image quantification of D(lung:muscle) ratio;f)Gdconcentration in lung tissue;g )GdOX uptake in bleomycin-challenged mouse, showing low lung enhancement in 14 day bleomycin-injured mice with negative control probe and h) GdOA in bleomycin-challenged mouse dosed daily for 14 days with BAPN, showing little lung enhancement, indicating an absence of allysine. (* = P < 0.05, ** = P < 0.01, *** = P < 0.001, n/s = not significant).
